These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 34108941

  • 21. SIADH with Severe Hyponatremia in an Elderly Man with Herpes Zoster Infection: A Causal or Casual Association?
    Foppiani L.
    Intern Med; 2018 Dec 01; 57(23):3393-3398. PubMed ID: 29984775
    [Abstract] [Full Text] [Related]

  • 22. Tolvaptan versus fluid restriction in acutely hospitalised patients with moderate-profound hyponatraemia (TVFR-HypoNa): design and implementation of an open-label randomised trial.
    Warren AM, Grossmann M, Hoermann R, Zajac JD, Russell N.
    Trials; 2022 Apr 21; 23(1):335. PubMed ID: 35449020
    [Abstract] [Full Text] [Related]

  • 23. Clinical experience with Tolvaptan outpatient use. Cost and effectiveness in 9 cases.
    Barajas-Galindo DE, Vidal-Casariego A, Gómez-Hoyos E, Guerra-González M.
    Gac Med Mex; 2020 Apr 21; 156(1):78-81. PubMed ID: 32026886
    [Abstract] [Full Text] [Related]

  • 24. Comparison of tolvaptan treatment between patients with the SIADH and congestive heart failure: a single-center experience.
    Park GH, Lee CM, Song JW, Jung MC, Kim JK, Song YR, Kim HJ, Kim SG.
    Korean J Intern Med; 2018 May 21; 33(3):561-567. PubMed ID: 28286940
    [Abstract] [Full Text] [Related]

  • 25. Tolvaptan for SIADH in Myelodysplastic Syndrome with Blast Crisis.
    Mali P, Muduganti SR, Mujibur R, Murali N.
    WMJ; 2015 Apr 21; 114(2):66-8. PubMed ID: 26756059
    [Abstract] [Full Text] [Related]

  • 26. [Treatment of hyponatremia: role of vaptans].
    Hensen J.
    Internist (Berl); 2010 Dec 21; 51(12):1499-509. PubMed ID: 21104220
    [Abstract] [Full Text] [Related]

  • 27. Vaptans are not the mainstay of treatment in hyponatremia: perhaps not yet.
    Gross PA, Wagner A, Decaux G.
    Kidney Int; 2011 Sep 21; 80(6):594-600. PubMed ID: 21451459
    [Abstract] [Full Text] [Related]

  • 28. Risk factors for sodium overcorrection in non-hypovolemic hyponatremia patients treated with tolvaptan.
    Kim Y, Lee N, Lee KE, Gwak HS.
    Eur J Clin Pharmacol; 2020 May 21; 76(5):723-729. PubMed ID: 32055900
    [Abstract] [Full Text] [Related]

  • 29. Use of conivaptan for management of hyponatremia following surgery for Cushing's disease.
    Breshears JD, Jiang B, Rowland NC, Kunwar S, Blevins LS.
    Clin Neurol Neurosurg; 2013 Nov 21; 115(11):2358-61. PubMed ID: 24041963
    [Abstract] [Full Text] [Related]

  • 30. Acute hyponatremia after aneurysmal subarachnoid hemorrhage: Frequency, treatment, and outcome.
    Kieninger M, Kerscher C, Bründl E, Bele S, Proescholdt M, Zeman F, Graf B, Schmidt NO, Schebesch KM.
    J Clin Neurosci; 2021 Jun 21; 88():237-242. PubMed ID: 33992191
    [Abstract] [Full Text] [Related]

  • 31. Diagnosis and treatment of hyponatraemia in neurosurgical patients.
    Cuesta M, Hannon MJ, Thompson CJ.
    Endocrinol Nutr; 2016 May 21; 63(5):230-8. PubMed ID: 26965574
    [Abstract] [Full Text] [Related]

  • 32. An economic analysis of tolvaptan compared with fluid restriction among hospitalized patients with hyponatremia.
    Ramamohan V, Mladsi D, Ronquest N, Kamat S, Boklage S.
    Hosp Pract (1995); 2017 Aug 21; 45(3):111-117. PubMed ID: 28449624
    [Abstract] [Full Text] [Related]

  • 33. [Hyponatremia : The water-intolerant patient].
    Hensen J.
    Med Klin Intensivmed Notfmed; 2012 Sep 21; 107(6):440-7. PubMed ID: 22911166
    [Abstract] [Full Text] [Related]

  • 34. 'Dos and don'ts' in the management of hyponatremia.
    Aylwin S, Burst V, Peri A, Runkle I, Thatcher N.
    Curr Med Res Opin; 2015 Sep 21; 31(9):1755-61. PubMed ID: 26173050
    [Abstract] [Full Text] [Related]

  • 35. [Lower doses of tolvaptan in hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion].
    Sánchez Sobrino P, Fernández Catalina P, Lorenzo Solar M, Rego Iraeta A.
    Med Clin (Barc); 2015 Aug 07; 145(3):138-9. PubMed ID: 25543222
    [No Abstract] [Full Text] [Related]

  • 36. [From hyponatremia to tolvaptan].
    Cernaro V, Santoro D, Lacquaniti A, Montalto G, Buemi M.
    G Ital Nefrol; 2014 Aug 07; 31(1):. PubMed ID: 24671837
    [Abstract] [Full Text] [Related]

  • 37. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
    Nemerovski C, Hutchinson DJ.
    Clin Ther; 2010 Jun 07; 32(6):1015-32. PubMed ID: 20637957
    [Abstract] [Full Text] [Related]

  • 38. SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptan.
    De Las Peñas R, Ponce S, Henao F, Camps Herrero C, Carcereny E, Escobar Álvarez Y, Rodríguez CA, Virizuela JA, López López R.
    Support Care Cancer; 2016 Jan 07; 24(1):499-507. PubMed ID: 26431960
    [Abstract] [Full Text] [Related]

  • 39. Tolvaptan Treatment in Children with Chronic Hyponatremia due to Inappropriate Antidiuretic Hormone Secretion: A Report of Three Cases.
    Tuli G, Tessaris D, Einaudi S, De Sanctis L, Matarazzo P.
    J Clin Res Pediatr Endocrinol; 2017 Sep 01; 9(3):288-292. PubMed ID: 28515029
    [Abstract] [Full Text] [Related]

  • 40. A Randomized Trial of Empagliflozin to Increase Plasma Sodium Levels in Patients with the Syndrome of Inappropriate Antidiuresis.
    Refardt J, Imber C, Sailer CO, Jeanloz N, Potasso L, Kutz A, Widmer A, Urwyler SA, Ebrahimi F, Vogt DR, Winzeler B, Christ-Crain M.
    J Am Soc Nephrol; 2020 Mar 01; 31(3):615-624. PubMed ID: 32019783
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.